Originally Posted by
Bigshotvictoria
It looks like there's a whole new breed of Racetams that have been, and are currently being developed called Ampakines. Aniracetam and Pariracetam exhibit ampkanine effects, but drugs specific to this mechanism of action are being developed, and one, CX717 is being heavily studied by the military for it's reported ability to enhance combat readiness in soldiers. Ampakines work by strongly interacting with glutamatergic AMPA receptors on the neurones, dramatically increasing attention span, alertness, and facilitating new learning and memory. I find this category of recetams, and CX717 interesting in particular because despite much of the research on this drug is based on treating Alzheimer's disease, Parkinson's disease, Schizophrenia, and ADHD; the majority of funding for clinical trials and testing comes from DARPA (Defense Advanced Research Projects Agency). From what I can find it seems as though the only problem with CX717 and to an even greater extent with prior Ampakines is the very low oral bioavalability. The absolute newest Ampakine is CX1739, produced by the same company as CX717, Cortex Pharmaceuticals. It is currently is phase 2 of clinical trials to treat ADHD, Alzheimers, and respiratory depression, as testing has shown that CX1739 has a profound effect on O2 saturation. These drugs look pretty interesting, and may be the next wave of Racetams.
